共 39 条
- [22] Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy Osteoporosis International, 2014, 25 : 2709 - 2719
- [26] Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial Journal of Bone and Mineral Metabolism, 2020, 38 : 310 - 315
- [28] Monthly intravenous alendronate treatment can maintain bone strength in osteogenesis imperfecta patients following cyclical pamidronate treatment JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2020, 33 (11): : 1391 - 1397
- [29] Correction to: Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial Journal of Bone and Mineral Metabolism, 2020, 38 : 605 - 605
- [30] Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients - A retrospective, observational study ARTHRITIS AND RHEUMATISM, 2003, 48 (04): : 1102 - +